IBDEI1XQ ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30907,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
 ;;^UTILITY(U,$J,358.3,30907,1,4,0)
 ;;=4^N04.2
 ;;^UTILITY(U,$J,358.3,30907,2)
 ;;=^5015533
 ;;^UTILITY(U,$J,358.3,30908,0)
 ;;=N04.3^^123^1597^56
 ;;^UTILITY(U,$J,358.3,30908,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30908,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30908,1,4,0)
 ;;=4^N04.3
 ;;^UTILITY(U,$J,358.3,30908,2)
 ;;=^5015534
 ;;^UTILITY(U,$J,358.3,30909,0)
 ;;=N04.4^^123^1597^54
 ;;^UTILITY(U,$J,358.3,30909,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30909,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30909,1,4,0)
 ;;=4^N04.4
 ;;^UTILITY(U,$J,358.3,30909,2)
 ;;=^5015535
 ;;^UTILITY(U,$J,358.3,30910,0)
 ;;=N04.5^^123^1597^57
 ;;^UTILITY(U,$J,358.3,30910,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30910,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
 ;;^UTILITY(U,$J,358.3,30910,1,4,0)
 ;;=4^N04.5
 ;;^UTILITY(U,$J,358.3,30910,2)
 ;;=^5015536
 ;;^UTILITY(U,$J,358.3,30911,0)
 ;;=N04.6^^123^1597^52
 ;;^UTILITY(U,$J,358.3,30911,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30911,1,3,0)
 ;;=3^Nephrotic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,30911,1,4,0)
 ;;=4^N04.6
 ;;^UTILITY(U,$J,358.3,30911,2)
 ;;=^5015537
 ;;^UTILITY(U,$J,358.3,30912,0)
 ;;=N04.7^^123^1597^53
 ;;^UTILITY(U,$J,358.3,30912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30912,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
 ;;^UTILITY(U,$J,358.3,30912,1,4,0)
 ;;=4^N04.7
 ;;^UTILITY(U,$J,358.3,30912,2)
 ;;=^5015538
 ;;^UTILITY(U,$J,358.3,30913,0)
 ;;=N04.8^^123^1597^60
 ;;^UTILITY(U,$J,358.3,30913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30913,1,3,0)
 ;;=3^Nephrotic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,30913,1,4,0)
 ;;=4^N04.8
 ;;^UTILITY(U,$J,358.3,30913,2)
 ;;=^5015539
 ;;^UTILITY(U,$J,358.3,30914,0)
 ;;=N04.9^^123^1597^61
 ;;^UTILITY(U,$J,358.3,30914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30914,1,3,0)
 ;;=3^Nephrotic syndrome w/ unspecified morphologic changes
 ;;^UTILITY(U,$J,358.3,30914,1,4,0)
 ;;=4^N04.9
 ;;^UTILITY(U,$J,358.3,30914,2)
 ;;=^5015540
 ;;^UTILITY(U,$J,358.3,30915,0)
 ;;=N05.0^^123^1597^49
 ;;^UTILITY(U,$J,358.3,30915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30915,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,30915,1,4,0)
 ;;=4^N05.0
 ;;^UTILITY(U,$J,358.3,30915,2)
 ;;=^5015541
 ;;^UTILITY(U,$J,358.3,30916,0)
 ;;=N05.1^^123^1597^48
 ;;^UTILITY(U,$J,358.3,30916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30916,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,30916,1,4,0)
 ;;=4^N05.1
 ;;^UTILITY(U,$J,358.3,30916,2)
 ;;=^5015542
 ;;^UTILITY(U,$J,358.3,30917,0)
 ;;=N05.2^^123^1597^45
 ;;^UTILITY(U,$J,358.3,30917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30917,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,30917,1,4,0)
 ;;=4^N05.2
 ;;^UTILITY(U,$J,358.3,30917,2)
 ;;=^5015543
 ;;^UTILITY(U,$J,358.3,30918,0)
 ;;=N05.3^^123^1597^46
 ;;^UTILITY(U,$J,358.3,30918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30918,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph
